GlaxoSmithKline Plc said on Tuesday that plaintiffs in the first scheduled U.S. lawsuit around heartburn drug Zantac will file a notice to voluntarily dismiss the case.
GSK's shares were hit last week by investor concerns about the litigation around potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}